Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-475 versus placebo added to current lipid-lowering therapy in homozygous familial hypercholesterolemia
2005-003626-26Phase 3Terminated
- Sponsor
- Takeda
- Start
- Nov 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in homozygous familial hypercholesterolemia (HoFH) and primary dyslipidaemia comparing TAK-475 + current lipid-lowering therapy with Placebo + current lipid-lowering therapy (2 arms). Primary endpoint: Fasting plasma low-density lipoprotein cholesterol concentration. Started Nov 2005; status: terminated.
02
Drugs
lapaquistat
03
Conditions
homozygous familial hypercholesterolemia (HoFH)primary dyslipidaemia
Beyond the preview
Go deeper on 2005-003626-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003626-26.